1. SpechlerSJ, SharmaP, SouzaRF, et al.American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology2011;140:e18. CrossRef

2. SpechlerSJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA2013;310:627. CrossRef

3. PohlH, SirovichB, WelchHG. Esophageal adenocarcinoma incidence: are we reaching the peak?Cancer Epidemiol Biomarkers Prev2010;19:1468. CrossRef

4. LagergrenJ, LagergrenP. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin2013;63:232. CrossRef

5. McClaveSA, BoyceHWJr, GottfriedMR. Early diagnosis of columnar‐lined esophagus: a new endoscopic criterion. Gastrointest Endosc1987;33:413. CrossRef

6. Choi doW, OhSN, BaekSJ, et al.Endoscopically observed lower esophageal capillary patterns. Korean J Intern Med2002;17:245. CrossRef

7. ViannaA, HayesPC, MoscosoG, et al.Normal venous circulation of the gastroesophageal junction. A route to understanding varices. Gastroenterology1987;93:876.

8. SpechlerSJ, ZeroogianJM, AntonioliDA, et al.Prevalence of metaplasia at the gastro‐oesophageal junction. Lancet1994;344:1533. CrossRef

9. SpechlerSJ. The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut1997;41:710. CrossRef

10. SharmaP, MoralesTG, SamplinerRE. Short segment Barrett's esophagus. The need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol1998;93:1033.

11. SharmaP, DentJ, ArmstrongD, et al.The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M Criteria. Gastroenterology2006;131:1392. CrossRef

12. PaullA, TrierJS, DaltonMD, et al.The histologic spectrum of Barrett's esophagus. N Engl J Med1976;295:476. CrossRef

13. ChandrasomaP. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg1997;9:270.

14. ChandrasomaPT. Histologic definition of gastro‐esophageal reflux disease. Curr Opin Gastroenterol2013;29:460. CrossRef

15. HahnHP, BlountPL, AyubK, et al.Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol2009;33:1006. CrossRef

16. LiuW, HahnH, OdzeRD, et al.Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell‐containing epithelium. Am J Gastroenterol2009;104:816. CrossRef

17. TakuboK, AidaJ, NaomotoY, et al.Cardiac rather than intestinal‐type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol2009;40:65. CrossRef

18. KeltyCJ, GoughMD, Van WykQ, et al.Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol2007;42:1271. CrossRef

19. RiddellRH, OdzeRD. Definition of Barrett's esophagus: time for a rethink–is intestinal metaplasia dead?Am J Gastroenterol2009;104:2588. CrossRef

20. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar‐lined oesophagus. A Report of the working party of the British Society of Gastroenterology, 2005. http://www.bsg.org.uk.

21. BarrettNR. Chronic peptic ulcer of the oesophagus and “oesophagitis.”Br J Surg1950;38:175. CrossRef

22. WesterhoffM, HovanL, LeeC, et al.Effects of dropping the requirement for goblet cells from the diagnosis of Barrett's esophagus. Clin Gastroenterol Hepatol2012;10:1232. CrossRef

23. American Gastroenterological Association, SpechlerSJ, SharmaP, et al.American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology2011;140:1084. CrossRef

24. CorreaP. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol1995;19(Suppl 1):S37. CrossRef

25. SpechlerSJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology2004;126:567. CrossRef

26. SharmaP, WestonAP, MoralesT, et al.Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut2000;46:9. CrossRef

27. WangKK, SamplinerRE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol2008;103:788. CrossRef

28. FennertyMB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology2003;125:586. CrossRef

29. OrmsbyAH, GoldblumJR, RiceTW, et al.Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol1999;30:288. CrossRef

30. JovanovicI, TzardiM, MouzasIA, et al.Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol2002;17:445.

31. GlickmanJN, WangH, DasKM, et al.Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction. An immunohistochemical study of cytokeratins 7 and 20, Das‐1 and 45 MI. Am J Surg Pathol2001;25:87. CrossRef

32. El‐ZimaityHMT, GrahamDY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol2001;96:1378. CrossRef

33. DasKM, PrasadI, GarlaS, et al.Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med1994;120:753. CrossRef

34. MoralesCP, SpechlerSJ. Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. Am J Gastroenterol2003;98:759. CrossRef

35. CameronAJ. Epidemiology of columnar‐lined esophagus and adenocarcinoma. Gastroenterol Clin N Am1997;26:487. CrossRef

36. HassallE. Esophageal metaplasia: definition and prevalence in childhood. Gastrointest Endosc2006;64:676. CrossRef

37. El‐SeragHB, GilgerMA, ShubMD, et al.The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc2006;64:671. CrossRef

38. SpechlerSJ, JainSK, TendlerDA, et al.Racial differences in the frequency of symptoms and complications of gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2002;16:1795. CrossRef

39. WangA, MattekNC, HolubJL, et al.Prevalence of complicated gastroesophageal reflux disease and Barrett's esophagus among racial groups in a multi‐center consortium. Dig Dis Sci2009;54:964. CrossRef

40. LagergrenJ. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol2011;8:340. CrossRef

41. CookMB, ShaheenNJ, AndersonLA, et al.Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology2012;142:744. CrossRef

42. RexDK, CummingsOW, ShawM, et al.Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology2003;125:1670. CrossRef

43. RonkainenJ, AroP, StorskrubbT, et al.Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology2005;129:1825. CrossRef

44. ChakA, Ochs‐BalcomH, FalkG, et al.Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev2006;15:1668. CrossRef

45. OrloffM, PetersonC, HeX, et al.Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA2011;306:410. CrossRef

46. BlotWJ, DevesaSS, KnellerRW, et al.Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA1991;265:1287. CrossRef

47. BlotWJ, DevesaSS, FraumeniJFJr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA1993;270:1320. CrossRef

48. LagergrenJ, BergstromR, LindgrenA, et al.Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med1999;340:825. CrossRef

49. SouzaRF, SpechlerSJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin2005;55:334. CrossRef

50. MansonJE, SkerrettPJ, GreenlandP, et al.The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med2004;164:249. CrossRef

51. HampelH, AbrahamNS, El‐SeragHB. Meta‐analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med2005;143:199. CrossRef

52. PandolfinoJE, El‐SeragHB, ZhangQ, et al.Obesity: a challenge to esophagogastric junction integrity. Gastroenterology2006;130:639. CrossRef

53. El‐SeragHB, ErgunGA, PandolfinoJ, et al.Obesity increases oesophageal acid exposure. Gut2007;56:749. CrossRef

54. KramerJR, FischbachLA, RichardsonP, et al.Waist‐to‐hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol2013;11:373. CrossRef

55. RenehanAG, FrystykJ, FlyvbjergA. Obesity and cancer risk: the role of the insulin‐IGF axis. Trends Endocrinol Metab2006;17:328. CrossRef

56. HodaMR, KeelySJ, BertelsenLS, et al.Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg2007;94:346. CrossRef

57. ArditiJD, VenihakiM, KaralisKP, et al.Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res2007;39:9. CrossRef

58. ParsonnetJ. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther1995;9(Suppl 2):45.

59. YeW, HeldM, LagergrenJ, et al.Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous‐cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst2004;96:388. CrossRef

60. VicariJJ, PeekRM, FalkGW, et al.The seroprevalence of cagA‐positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology1998;115:50. CrossRef

61. DelaneyB, McCollK. Review article: Helicobacter pylori and gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2005;22(Suppl 1):32. CrossRef

62. RichterJE. H. pylori: the bug is not all bad. Gut2001;49:319.

63. CorleyDA, KerlikowskeK, VermaR, et al.Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta‐analysis. Gastroenterology2003;124:47. CrossRef

64. KasteleinF, SpaanderMC, BiermannK, et al.; Probar‐study Group. Nonsteroidal anti‐inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology2011;141:2000. CrossRef

65. TerryP, LagergrenJ, HansenH, et al.Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev2001;10:365. CrossRef

66. LagergrenJ. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?Gut2005;54(Suppl 1):i1. CrossRef

67. ShaheenNJ, CrosbyMA, BozymskiEM, et al.Is there publication bias in the reporting of cancer risk in Barrett's esophagus?Gastroenterology2000;119:333. CrossRef

68. DrewitzDJ, SamplinerRE, GarewalHS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol1997;92:212.

69. DesaiTK, KrishnanK, SamalaN, et al.The incidence of oesophageal adenocarcinoma in non‐dysplastic Barrett's oesophagus: a meta‐analysis. Gut2012;61:970. CrossRef

70. WaniS, FalkG, HallM, et al.Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol2011;9:220. CrossRef

71. BhatS, ColemanHG, YousefF, et al.Risk of malignant progression in Barrett's esophagus patients: results from a large population‐based study. J Natl Cancer Inst2011;103:1049. CrossRef

72. Hvid‐JensenF, PedersenL, DrewesAM, et al.Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med2011;365:1375. CrossRef

73. GaddamS, SinghM, BalasubramanianG, et al.Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology2013;145:548. CrossRef

74. IftikharSY, JamesPD, SteeleRJ, et al.Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut1992;33:1155. CrossRef

75. Menke‐PluymersMB, HopWC, DeesJ, et al.Risk factors for the development of an adenocarcinoma in columnar‐lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer1993;72:1155. CrossRef

76. WestonAP, KrmpotichPT, CherianR, et al.Prospective long‐term endoscopic and histological follow‐up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol1997;92:407.

77. HirotaWK, LoughneyTM, LazasDJ, et al.Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology1999;116:277. CrossRef

78. O′ConnorJB, FalkGW, RichterJE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol1999;94:2037.

79. AvidanB, SonnenbergA, SchnellTG, et al.Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol2002;97:1930. CrossRef

80. AnaparthyR, GaddamS, KanakadandiV, et al.Association between length of Barrett's esophagus and risk of high‐grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol2013;11:1430. CrossRef

81. RudolphRE, VaughanTL, StorerBE, et al.Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med2000;132:612. CrossRef

82. BurkeZD, ToshD. Barrett's metaplasia as a paradigm for understanding the development of cancer. Curr Opin Genet Dev2012;22:494. CrossRef

83. CollenMJ, LewisJH, BenjaminSB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology1990;98:654.

84. MulhollandMW, ReidBJ, LevineDS, et al.Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci1989;34:1329. CrossRef

85. GillenP, KeelingP, ByrnePJ, et al.Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg1988;75:540. CrossRef

86. IasconeC, DeMeesterTR, LittleAG, et al.Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg1983;118:543. CrossRef

87. ZaninottoG, DeMeesterTR, BremnerCG, et al.Esophageal function in patients with reflux–induced strictures and its relevance to surgical treatment. Ann Thorac Surg1989;47:362. CrossRef

88. JohnsonDA, WintersC, SpurlingTJ, et al.Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol1987;9:23. CrossRef

89. GrayMR, DonnellyRJ, KingsnorthAN. Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus. Br J Surg1991;78:1461. CrossRef

90. HirschowitzBI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci1996;41:1384. CrossRef

91. KahrilasPJ, McCollK, FoxM, et al.The acid pocket: a target for treatment in reflux disease?Am J Gastroenterol2013;108:1058. CrossRef

92. FletcherJ, WirzA, HenryE, et al.Studies of acid exposure immediately above the gastro‐oesophageal junction: evidence of short segment reflux. Gut2004;53:168. CrossRef

93. PandolfinoJE, LeeTJ, SchreinerMA, et al.Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus2006;19:177. CrossRef

94. IijimaK, HenryE, MoriyaA, et al.Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology2002;122:1248. CrossRef

95. SpechlerSJ. Are we underestimating acid reflux?Gut2004;53:162. CrossRef

96. JankowskiJA, WrightNA, MeltzerSJ, et al.Molecular evolution of the metaplasia‐dysplasia‐adenocarcinoma sequence in the esophagus. Am J Pathol1999;154:965. CrossRef

97. PeraM, PeraM. Experimental Barrett's esophagus and the origin of intestinal metaplasia. Chest Surg Clin N Am2002;12:25. CrossRef

98. SeeryJP. Stem cells of the oesophageal epithelium. J Cell Sci2002;115:1783.

99. GlickmanJN, SpechlerSJ, SouzaRF, et al.Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol2009;33:818. CrossRef

100. BochJA, ShieldsHM, AntonioliDA, et al.Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology1997;112:760. CrossRef

101. SawhneyRA, ShieldsHM, AllanCH, et al.Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci1996;41:1088. CrossRef

102. SarosiG, BrownG, JaiswalK, et al.Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus2008;21:43.

103. QuanteM, BhagatG, AbramsJA, et al.Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett‐like metaplasia. Cancer Cell2012;21:36. CrossRef

104. WangX, OuyangH, YamamotoY, et al.Residual embryonic cells as precursors of a Barrett's‐like metaplasia. Cell2011;145:1023. CrossRef

105. QueJ, OkuboT, GoldenringJR, et al.Multiple dose‐dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development2007;134:2521. CrossRef

106. DanielyY, LiaoG, DixonD, et al.Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol2004;287:C171. CrossRef

107. ChenX, QinR, LiuB, et al.Multilayered epithelium in a rat model and human Barrett's esophagus: similar expression patterns of transcription factors and differentiation markers. BMC Gastroenterol2008;8:1. CrossRef

108. GlickmanJN, YangA, ShahsafaeiA, et al.Expression of p53‐related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol2001;32:1157. CrossRef

109. QueJ, ChoiM, ZielJW, et al.Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation2006;74:422. CrossRef

110. MilanoF, van BaalJW, ButtarNS, et al.Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology2007;132:2412. CrossRef

111. WangDH, ClemonsNJ, MiyashitaT, et al.Aberrant epithelial‐mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology2010;138:1810. CrossRef

112. LitingtungY, LeiL, WestphalH, et al.Sonic hedgehog is essential to foregut development. Nat Genet1998;20:58. CrossRef

113. SuZ, GayLJ, StrangeA, et al.Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet2012;44:1131. CrossRef

114. MadisonBB, McKennaLB, DolsonD, et al.FoxF1 and FoxL1 link hedgehog signaling and the control of epithelial proliferation in the developing stomach and intestine. J Biol Chem2009;284:5936. CrossRef

115. GibsonMK, ZaidiAH, DavisonJM, et al.Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg2013;258:82. CrossRef

116. van de WeteringM, SanchoE, VerweijC, et al.The beta‐catenin/TCF‐4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell2002;111:241. CrossRef

117. LickertH, DomonC, HulsG, et al.Wnt/(beta)‐catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development2000;127:3805.

118. BianYS, OsterheldMC, BosmanFT, et al.Nuclear accumulation of beta‐catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol2000;114:583. CrossRef

119. MoyesLH, McEwanH, RadulescuS, et al.Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus. J Pathol2012;228:99.

120. FreS, HuygheM, MourikisP, et al.Notch signals control the fate of immature progenitor cells in the intestine. Nature2005;435:964. CrossRef

121. StangerBZ, DatarR, MurtaughLC, et al.Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A2005;102:12443. CrossRef

122. van EsJH, van GijnME, RiccioO, et al.Notch/gamma‐secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature2005;435:959. CrossRef

123. TamagawaY, IshimuraN, UnoG, et al.Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab Invest2012;92:896. CrossRef

124. MorrowDJ, AvissarNE, ToiaL, et al.Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery2009;146:714. CrossRef

125. WeinbergRA. The retinoblastoma protein and cell cycle control. Cell1995;81:323. CrossRef

126. ArberN, GammonMD, HibshooshH, et al.Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol1999;30:1087. CrossRef

127. SarbiaM, BektasN, MullerW, et al.Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer1999;86:2597. CrossRef

128. LinL, PrescottMS, ZhuZ, et al.Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res2000;60:7021.

129. GeddertH, HeepHJ, GabbertHE, et al.Expression of cyclin B1 in the metaplasia‐dysplasia‐carcinoma sequence of Barrett esophagus. Cancer2002;94:212. CrossRef

130. SarbiaM, ArjumandJ, WolterM, et al.Frequent c‐myc amplification in high‐grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol2001;115:835. CrossRef

131. TselepisC, MorrisCD, WakelinD, et al.Upregulation of the oncogene c‐myc in Barrett's adenocarcinoma: induction of c‐myc by acidified bile acid in vitro. Gut2003;52:174. CrossRef

132. LordRV, O′GradyR, SheehanC, et al.K‐ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol2000;15:730. CrossRef

133. SommererF, ViethM, MarkwarthA, et al.Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene2004;23:554. CrossRef

134. DulakAM, StojanovP, PengS, et al.Exome and whole‐genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet2013;45:478. CrossRef

135. JankowskiJ, McMeneminR, HopwoodD, et al.Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Colch)1991;81:663. CrossRef

136. HaighCR, AttwoodSE, ThompsonDG, et al.Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology2003;124:615. CrossRef

137. HarrisJC, ClarkePA, AwanA, et al.An antiapoptotic role for gastrin and the gastrin/CCK‐2 receptor in Barrett's esophagus. Cancer Res2004;64:1915. CrossRef

138. SouzaRF, ShewmakeK, TeradaLS, et al.Acid exposure activates the mitogen‐activated protein kinase pathways in Barrett's esophagus. Gastroenterology2002;122:299. CrossRef

139. JaiswalK, Lopez‐GuzmanC, SouzaRF, et al.Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non‐neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol2006;290:G335. CrossRef

140. FeaginsLA, SusnowN, ZhangHY, et al.Gain of allelic gene expression for IGF‐II occurs frequently in Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol2006;290:G871. CrossRef

141. IravaniS, ZhangHQ, YuanZQ, et al.Modification of insulin‐like growth factor 1 receptor, c‐Src, and Bcl‐XL protein expression during the progression of Barrett's neoplasia. Hum Pathol2003;34:975. CrossRef

142. HerreraLJ, El HefnawyT, Queiroz de OliveiraPE, et al.The HGF receptor c‐Met is overexpressed in esophageal adenocarcinoma. Neoplasia2005;7:75. CrossRef

143. JankowskiJ, CoghillG, HopwoodD, et al.Oncogenes and onco‐suppressor gene in adenocarcinoma of the oesophagus. Gut1992;33:1033. CrossRef

144. FlejouJF, ParafF, MuzeauF, et al.Expression of c‐erbB‐2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol1994;47:23. CrossRef

145. BrienTP, OdzeRD, SheehanCE, et al.HER‐2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus‐associated adenocarcinoma. Hum Pathol2000;31:35. CrossRef

146. BoyntonRF, HuangY, BlountPL, et al.Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res1991;51:5766.

147. HuangY, MeltzerSJ, YinJ, et al.Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res1993;53:1889.

148. CoppolaD, SchreiberRH, MoraL, et al.Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol1999;6:298. CrossRef

149. SarbiaM, TekinU, ZeriouhM, et al.Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus. Anticancer Res2001;21:387.

150. GiacciaAJ, KastanMB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev1998;12:2973. CrossRef

151. SerranoM, HannonGJ, BeachD. A new regulatory motif in cell‐cycle control causing specific inhibition of cyclin D/CDK4. Nature1993;366:704. CrossRef

152. HannonGJ, BeachD. p15INK4B is a potential effector of TGF‐beta‐induced cell cycle arrest. Nature1994;371:257. CrossRef

153. BlountPL, GalipeauPC, SanchezCA, et al.17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res1994;54:2292.

154. BarrettMT, SanchezCA, PrevoLJ, et al.Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet1999;22:106. CrossRef

155. GalipeauPC, CowanDS, SanchezCA, et al.17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A1996;93:7081. CrossRef

156. RamelS, ReidBJ, SanchezCA, et al.Evaluation of p53 protein expression in Barrett's esophagus by two‐parameter flow cytometry [see comments]. Gastroenterology1992;102:1220.

157. YounesM, LebovitzRM, LechagoLV, et al.p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow‐up study. Gastroenterology1993;105:1637.

158. FlejouJF, PotetF, MuzeauF, et al.Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol1993;46:330. CrossRef

159. HamelinR, FlejouJF, MuzeauF, et al.TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology1994;107:1012. CrossRef

160. MoskalukCA, HeitmillerR, ZahurakM, et al.p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol1996;27:1211. CrossRef

161. Rioux‐LeclercqN, TurlinB, SutherlandF, et al.Analysis of Ki‐67, p53 and Bcl‐2 expression in the dysplasia‐carcinoma sequence of Barrett's esophagus. Oncol Rep1999;6:877.

162. KimR, ClarkeMR, MelhemMF, et al.Expression of p53, PCNA, and C‐erbB‐2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci1997;42:2453. CrossRef

163. GalipeauPC, PrevoLJ, SanchezCA, et al.Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst1999;91:2087. CrossRef

164. MeltzerSJ, YinJ, HuangY, et al.Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A1991;88:4976. CrossRef

165. BarrettMT, SanchezCA, GalipeauPC, et al.Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene1996;13:1867.

166. WongDJ, BarrettMT, StogerR, et al.p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res1997;57:2619.

167. BarrettMT, GalipeauPC, SanchezCA, et al.Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene1996;12:1873.

168. MaleyCC, GalipeauPC, LiX, et al.The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res2004;64:7629. CrossRef

169. KawamataN, MorosettiR, MillerCW, et al.Wilcyznski S. Molecular analysis of the cyclin‐dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res1995;55:2266.

170. SinghSP, LipmanJ, GoldmanH, et al.Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res1998;58:1730.

171. DolanK, GardeJ, WalkerSJ, et al.LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol1999;30:1508. CrossRef

172. PowellSM, PapadopoulosN, KinzlerKW, et al.APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology1994;107:1759.

173. RajaS, FinkelsteinSD, BakshFK, et al.Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg2001;72:1130. CrossRef

174. EadsCA, LordRV, KurumboorSK, et al.Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res2000;60:5021.

175. ClementG, BraunschweigR, PasquierN, et al.Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol2006;208:100. CrossRef

176. KawakamiK, BrabenderJ, LordRV, et al.Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma. J Natl Cancer Inst2000;92:1805. CrossRef

177. TselepisC, PerryI, DawsonC, et al.Tumour necrosis factor‐alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene2002;21:6071. CrossRef

178. AshkenaziA, DixitVM. Death receptors: signaling and modulation. Science1998;281:1305. CrossRef

179. NagataS. Apoptosis by death factor. Cell1997;88:355. CrossRef

180. HsuH, ShuHB, PanMG, et al.TRADD‐TRAF2 and TRADD‐FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell1996;84:299. CrossRef

181. WhitesideST, IsraelA. I kappa B proteins: structure, function and regulation. Semin Cancer Biol1997;8:75. CrossRef

182. Li‐WeberM, KrammerPH. Function and regulation of the CD95 (APO‐1/Fas) ligand in the immune system. Semin Immunol2003;15:145. CrossRef

183. van der WoudeCJ, JansenPL, TieboschAT, et al.Expression of apoptosis‐related proteins in Barrett's metaplasia‐dysplasia‐carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol2002;33:686. CrossRef

184. HughesSJ, NambuY, SoldesOS, et al.Fas/APO‐1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res1997;57:5571.

185. YounesM, LechagoJ, ErtanA, et al.Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus [In Process Citation]. Hum Pathol2000;31:434. CrossRef

186. IgneyFH, KrammerPH. Tumor counterattack: fact or fiction?Cancer Immunol Immunother2005;54:1127. CrossRef

187. YounesM, SchwartzMR, ErtanA, et al.Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer2000;88:524. CrossRef

188. KatadaN, HinderRA, SmyrkTC, et al.Apoptosis is inhibited early in the dysplasia‐carcinoma sequence of Barrett esophagus. Arch Surg1997;132:728. CrossRef

189. RaoufAA, EvoyDA, CartonE, et al.Loss of Bcl‐2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus2003;16:17. CrossRef

190. ShureiqiI, XuX, ChenD, et al.Nonsteroidal anti‐inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15‐lipoxygenase‐1 expression. Cancer Res2001;61:4879.

191. TsujiiM, DuBoisRN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell1995;83:493. CrossRef

192. ElderDJ, HaltonDE, HagueA, et al.Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase‐2 (COX‐2)‐selective nonsteroidal anti‐inflammatory drug: independence from COX‐2 protein expression. Clin Cancer Res1997;3:1679.

193. WilsonKT, FuS, RamanujamKS, et al.Increased expression of inducible nitric oxide synthase and cyclooxygenase‐2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res1998;58:2929.

194. ZimmermannKC, SarbiaM, WeberAA, et al.Cyclooxygenase‐2 expression in human esophageal carcinoma. Cancer Res1999;59:198.

195. KandilHM, TannerG, SmalleyW, et al.Cyclooxygenase‐2 Expression in Barrett's Esophagus. Dig Dis Sci2001;46:785. CrossRef

196. SouzaRF, ShewmakeK, BeerDG, et al.Selective inhibition of Cyclooxygenase‐2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res2000;60:5767.

197. Abdel‐latifMM, O′RiordanJ, WindleHJ, et al.NF‐kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg2004;239:491. CrossRef

198. O′RiordanJM, Abdel‐latifMM, RaviN, et al.Proinflammatory cytokine and nuclear factor kappa‐B expression along the inflammation‐metaplasia‐dysplasia‐adenocarcinoma sequence in the esophagus. Am J Gastroenterol2005;100:1257. CrossRef

199. HuoX, JuergensS, ZhangX, et al.Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF‐κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol2011;301:G278. CrossRef

200. LordRV, SalongaD, DanenbergKD, et al.Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg2000;4:135. CrossRef

201. MoralesCP, LeeEL, ShayJW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer1998;83:652. CrossRef

202. Palanca‐WesselsMC, BarrettMT, GalipeauPC, et al.Genetic analysis of long‐term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology1998;114:295. CrossRef

203. JaiswalKR, MoralesCP, FeaginsLA, et al.Characterization of telomerase‐immortalized, non‐neoplastic, human Barrett's cell line (BAR‐T). Dis Esophagus2007;20:256. CrossRef

204. ShammasMA, KoleyH, BeerDG, et al.Growth arrest, apoptosis, and telomere shortening of Barrett's‐associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology2004;126:1337. CrossRef

205. AuvinenMI, SihvoEI, RuohtulaT, et al.Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol2002;20:2971. CrossRef

206. CouvelardA, ParafF, GratioV, et al.Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol2000;192:14. CrossRef

207. SihvoEI, RuohtulaT, AuvinenMI, et al.Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg2003;126:1952. CrossRef

208. MobiusC, SteinHJ, BeckerI, et al.The ′angiogenic switch′ in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol2003;29:890. CrossRef

209. AchenMG, JeltschM, KukkE, et al.Vascular endothelial growth factor D (VEGF‐D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A1998;95:548. CrossRef

210. von RahdenBH, SteinHJ, PuhringerF, et al.Coexpression of cyclooxygenases (COX‐1, COX‐2) and vascular endothelial growth factors (VEGF‐A, VEGF‐C) in esophageal adenocarcinoma. Cancer Res2005;65:5038. CrossRef

211. LordRV, ParkJM, WickramasingheK, et al.Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg2003;125:246. CrossRef

212. SeeryJP, SyrigosKN, KarayiannakisAJ, et al.Abnormal expression of the E‐cadherin‐catenin complex in dysplastic Barrett's oesophagus. Acta Oncol1999;38:945. CrossRef

213. FeithM, SteinHJ, MuellerJ, et al.Malignant degeneration of Barrett's esophagus: the role of the Ki‐67 proliferation fraction, expression of E‐cadherin and p53. Dis Esophagus2004;17:322. CrossRef

214. SwamiS, KumbleS, TriadafilopoulosG. E‐cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol1995;90:1808.

215. WashingtonK, ChiapporiA, HamiltonK, et al.Expression of beta‐catenin, alpha‐catenin, and E‐cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol1998;11:805.

216. BaileyT, BiddlestoneL, ShepherdN, et al.Altered cadherin and catenin complexes in the Barrett's esophagus‐dysplasia‐adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol1998;152:135.

217. CoussensLM, FingletonB, MatrisianLM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science2002;295:2387. CrossRef

218. PenderSL, MacDonaldTT. Matrix metalloproteinases and the gut – new roles for old enzymes. Curr Opin Pharmacol2004;4:546. CrossRef

219. SalmelaMT, Karjalainen‐LindsbergML, PuolakkainenP, et al.Upregulation and differential expression of matrilysin (MMP‐7) and metalloelastase (MMP‐12) and their inhibitors TIMP‐1 and TIMP‐3 in Barrett's oesophageal adenocarcinoma. Br J Cancer2001;85:383. CrossRef

220. ClemonsNJ, ShannonNB, AbeyratneLR, et al.Nitric oxide‐mediated invasion in Barrett's high‐grade dysplasia and adenocarcinoma. Carcinogenesis2010;31:1669. CrossRef

221. HanahanD, WeinbergRA. The hallmarks of cancer. Cell2000;100:57. CrossRef

222. FritcherEG, BrankleySM, KippBR, et al.A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol2008;39:1128. CrossRef

223. HuangQ, YuC, ZhangX, et al.Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. BMC Clin Pathol2008;8:5. CrossRef

224. RygielAM, van BaalJW, MilanoF, et al.Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer2007;109:1980. CrossRef

225. HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell2011;144:646. CrossRef

226. PicardoSL, MaherSG, O'SullivanJN, et al.Barrett's to oesophageal cancer sequence: a model of inflammatory‐driven upper gastrointestinal cancer. Dig Surg2012;29:251. CrossRef

227. DvorakK, ChavarriaM, PayneCM, et al.Activation of the interleukin‐6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res2007;13:5305. CrossRef

228. ZhangHY, ZhangQ, ZhangX, et al.Cancer‐related inflammation and Barrett's carcinogenesis: interleukin‐6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol2011;300:G454. CrossRef

229. HauraEB, TurksonJ, JoveR. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol2005;2:315. CrossRef

230. SpechlerSJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol2005;100:927. CrossRef

231. OdzeRD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr Opin Gastroenterol2011;27:389. CrossRef

232. ReidBJ, HaggittRC, RubinCE. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol1988;19:166. CrossRef

233. SkacelM, PetrasRE, GramlichTL, et al.The diagnosis of low‐grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol2000;95:3383. CrossRef

234. MontgomeryE, BronnerMP, GoldblumJR, et al.Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol2001;32:368. CrossRef

235. OrmsbyAH, PetrasRE, HenricksWH, et al.Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut2002;51:671. CrossRef

236. CocoDP, GoldblumJR, HornickJL, et al.Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol2011;35:45. CrossRef

237. KaraMA, PetersFP, Ten KateFJ, et al.Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc2005;61:679. CrossRef

238. ReidBJ, WeinsteinWM, LewinKJ, et al.Endoscopic biopsy can detect high‐grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology1988;94:81.

239. CameronAJ, CarpenterHA. Barrett's esophagus, high‐grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol1997;92:586.

240. LevineDS, HaggittRC, BlountPL, et al.An endoscopic biopsy protocol can differentiate high‐grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology1993;105:40.

241. CollardJM. High‐grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am2002;12:77. CrossRef

242. KondaVJ, RossAS, FergusonMK, et al.Is the risk of concomitant invasive esophageal cancer in high‐grade dysplasia in Barrett's esophagus overestimated?Clin Gastroenterol Hepatol2008;6:159. CrossRef

243. CurversWL, BergmanJJ. Multimodality imaging in Barrett's esophagus: looking longer, seeing better, and recognizing more. Gastroenterology2008;135:297. CrossRef

244. Fels ElliottDR, FitzgeraldRC. Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol2013;29:437. CrossRef

245. PrasadGA, ButtarNS, WongkeesongLM, et al.Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol2007;102:2380. CrossRef

246. SturmMB, JoshiBP, LuS, et al.Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first‐in‐human results. Sci Transl Med2013;5:184ra61. CrossRef

247. Bird‐LiebermanEL, NevesAA, Lao‐SirieixP, et al.Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med2012;18:315. CrossRef

248. KasteleinF, BiermannK, SteyerbergEW, et al.; on behalf of the ProBar‐study group. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut2013;62:1676. CrossRef

249. ReidBJ, LevineDS, LongtonG, et al.Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low‐ and high‐risk patient subsets. Am J Gastroenterol2000;95:1669.

250. Bird‐LiebermanEL, DunnJM, ColemanHG, et al.Population‐based study reveals new risk‐stratification biomarker panel for Barrett's esophagus. Gastroenterology2012;143:927. CrossRef

251. JinZ, ChengY, GuW, et al.A multicenter, double‐blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res2009;69:4112. CrossRef

252. AlviMA, LiuX, O'DonovanM, et al.DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early‐stage neoplasia in Barrett's esophagus. Clin Cancer Res2013;19:878. CrossRef

253. SchnellTG, SontagSJ, ChejfecG, et al.Long‐term nonsurgical management of Barrett's esophagus with high‐grade dysplasia. Gastroenterology2001;120:1607. CrossRef

254. O'ConnorJB, FalkGW, RichterJE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Report on the Cleveland Clinic Barrett's esophagus registry. Am J Gastroenterol1999;94:2037.

255. SharmaP, FalkGW, WestonAP, et al.Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol2006;4:566. CrossRef

256. WestonAP, BanerjeeSK, SharmaP, et al.p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol2001;96:1355. CrossRef

257. CurversWL, ten KateFJ, KrishnadathKK, et al.Low‐grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol2010;105:1523. CrossRef

258. HameetemanW, TytgatGNJ, HouthoffHJ, et al.Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology1989;96:1249.

259. SpechlerSJ. Disputing dysplasia. Gastroenterology2001;120:1864. CrossRef

260. SamplinerRE, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol2002;97:1888. CrossRef

261. ButtarNS, WangKK, SeboTJ, et al.Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology2001;120:1630. CrossRef

262. DarMS, GoldblumJR, RiceTW, et al.Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?Gut2003;52:486. CrossRef

263. WestonAP, Sharma PrateekS, TopalovskiM, et al.Long‐term follow‐up of Barrett's high‐grade dysplasia. Am J Gastroenterol2000;95:1888. CrossRef

264. KatzPO, GersonLB, VelaMF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol2013;108:308. CrossRef

265. ZhangHY, Hormi‐CarverK, ZhangX, et al.In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double strand breaks. Cancer Res2009;69:9083. CrossRef

266. SouzaRF, ShewmakeK, TeradaLS, et al.Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology2002;122:299. CrossRef

267. Ouatu‐LascarR, FitzgeraldRC, TriadafilopoulosG. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology1999;117:327. CrossRef

268. PetersFT, GaneshS, KuipersEJ, et al.Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol2000;35:1238. CrossRef

269. SrinivasanR, KatzPO, RamakrishnanA, et al.Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther2001;15:519. CrossRef

270. El‐SeragHB, AguirreTV, DavisS, et al.Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol2004;99:1877. CrossRef

271. NguyenDM, El‐SeragHB, HendersonL, et al.Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol2009;7:1299. CrossRef

272. HillmanLC, ChiragakisL, ShadboltB, et al.Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust2004;180:387.

273. KasteleinF, SpaanderMC, SteyerbergEW, et al.; ProBar‐study group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol2013;11:382. CrossRef

274. KatzkaDA, CastellDO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol1994;89:989.

275. YehRW, GersonLB, TriadafilopoulosG. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus2003;16:193. CrossRef

276. GersonLB, BoparaiV, UllahN, et al.Oesophageal and gastric pH profiles in patients with gastro‐oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther2004;20:637. CrossRef

277. MalfertheinerP, LindT, WillichS, et al.Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro‐oesophageal reflux disease (GORD) and symptom resolution in non‐erosive GORD: report from the ProGORD study. Gut2005;54:746. CrossRef

278. SpechlerSJ, SharmaP, TraxlerB, et al.Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double‐blind, crossover trial. Am J Gastroenterol2006;101:1964. CrossRef

279. DeMeesterSR, DeMeesterTR. Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg2000;231:303. CrossRef

280. KatzD, RothsteinR, SchnedA, et al.The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol1998;93:536. CrossRef

281. ObergS, WennerJ, JohanssonJ, et al.Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg2005;242:49. CrossRef

282. SpechlerSJ, LeeE, AhnenD, et al.Long‐term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow‐up of a randomized controlled trial. JAMA2001;285:2331. CrossRef

283. YeW, ChowWH, LagergrenJ, et al.Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology2001;121:1286. CrossRef

284. TranT, SpechlerSJ, El‐SeragHB. Fundoplication and the risk of cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol2005;100:1002. CrossRef

285. LagergrenJ, YeW, LagergrenP, et al.The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology2010;138:1297. CrossRef

286. CoreyKE, SchmitzSM, ShaheenNJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta‐analysis. Am J Gastroenterol2003;98:2390. CrossRef

287. ChangEY, MorrisCD, SeltmanAK, et al.The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg2007;246:11. CrossRef

288. CameronAJ, OttBJ, PayneWS. The incidence of adenocarcinoma in columnar‐lined (Barrett's) esophagus. N Engl J Med1985;313:857. CrossRef

289. Van der VeenAH, DeesJ, BlankensteijnJD, et al.Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut1989;30:14. CrossRef

290. EckardtVF, KanzlerG, BernhardG. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med2001;111:33. CrossRef

291. AndersonLA, MurrayLJ, MurphySJ, et al.Mortality in Barrett's oesophagus: results from a population based study. Gut2003;52:1081. CrossRef

292. Solaymani‐DodaranM, LoganRF, WestJ, et al.Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses‐a population‐based cohort study. Am J Gastroenterol2005;100:2616. CrossRef

293. StreitzJMJr, AndrewsCWJr, EllisFHJr. Endoscopic surveillance of Barrett's esophagus. Does it help?J Thorac Cardiovasc Surg1993;105:383.

294. PetersJH, ClarkGWB, IrelandAP, et al.Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg1994;108:813.

295. CorleyDA, LevinTR, HabelLA, et al.Surveillance and survival in Barrett's adenocarcinomas: a population‐based study. Gastroenterology2002;122:633. CrossRef

296. FountoulakisA, ZafirellisKD, DolanK, et al.Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg2004;91:997. CrossRef

297. ShaheenNJ, ProvenzaleD, SandlerRS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol2002;97:1319. CrossRef

298. MacdonaldCE, WicksAC, PlayfordRJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ2000;321:1252. CrossRef

299. ProvenzaleD, SchmittC, WongJB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol1999;94:2043. CrossRef

300. SoniA, SamplinerRE, SonnenbergA. Screening for high‐grade dysplasia in gastroesophageal reflux disease: is it cost‐effective?Am J Gastroenterol2000;95:2086. CrossRef

301. SonnenbergA, SoniA, SamplinerRE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther2002;16:41. CrossRef

302. InadomiJM, SamplinerR, LagergrenJ, et al.Screening and surveillance for Barrett esophagus in high‐risk groups: a cost‐utility analysis. Ann Intern Med2003;138:176. CrossRef

303. GersonLB, GroeneveldPW, TriadafilopoulosG. Cost‐effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol2004;2:868. CrossRef

304. HurC, NishiokaNS, GazelleGS. Cost‐effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst2004;96:316. CrossRef

305. RubensteinJH, InadomiJM, BrillJV, et al.Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol2007;5:312. CrossRef

306. GersonL, LinOS. Cost‐benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol2007;5:319. CrossRef

307. ASGE Standards of Practice Committee, EvansJA, EarlyDS, et al.The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc2012;76:1087. CrossRef

308. van der BurghA, DeesJ, HopWC, et al.Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut1996;39:5. CrossRef

309. RubensteinJH, SonnenbergA, DavisJ, et al.Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc2008;68:849. CrossRef

310. CorleyDA, MehtaniK, QuesenberryC, et al.Impact of endoscopic surveillance on mortality from Barrett's esophagus‐associated esophageal adenocarcinomas. Gastroenterology2013;145:312. CrossRef

311. SpechlerSJ. Screening and surveillance for Barrett's esophagus — an unresolved dilemma. Nat Clin Pract Gastroenterol Hepatol2007;4:470. CrossRef

312. ShaheenNJ, DulaiGS, AscherB, et al.Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol2005;100:577. CrossRef

313. CrockettSD, LippmannQK, DellonES, et al.Health‐related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol2009;7:613. CrossRef

314. ReidBJ, BlountPL, FengZ, et al.Optimizing endoscopic biopsy detection of early cancers in Barrett's high‐grade dysplasia. Am J Gastroenterol2000;95:3089. CrossRef

315. BoshierPR, AndersonO, HannaGB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta‐analysis. Ann Surg2011;254:894. CrossRef

316. KarlRC, SchreiberR, BoulwareD, et al.Factors affecting morbidity, mortality, and survival in patients undergoing Ivor‐Lewis esophagogastrectomy. Ann Surg2000;231:635. CrossRef

317. YoungMM, DeschampsC, TrastekVF, et al.Esophageal reconstruction for benign disease: early morbidity, mortality, and functional results. Ann Thorac Surg2000;70:1651. CrossRef

318. Van LanschotJJB, HulscherJBF, BuskensCJ, et al.Hospital volume and hospital mortality for esophagectomy. Cancer2001;91:1574. CrossRef

319. ChangLC, OelschlagerBK, QuirogaE, et al.Long‐term outcome of esophagectomy for high‐grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg2006;10:341. CrossRef

320. MoracaRJ, LowDE. Outcomes and health‐related quality of life after esophagectomy for high‐grade dysplasia and intramucosal cancer. Arch Surg2006;141:545. CrossRef

321. RosmolenWD, BoerKR, de LeeuwRJ, et al.Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus. Endoscopy2010;42:525. CrossRef

322. ZehetnerJ, DeMeesterSR, HagenJA, et al.Endoscopic resection and ablation versus esophagectomy for high‐grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg2011;141:39. CrossRef

323. DunbarKB. Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus. Curr Opin Gastroenterol2013;29:446. CrossRef

324. DunbarKB, SpechlerSJ. The risk of lymph node metastases in patients with high grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol2012;107:850. CrossRef

325. LeersJM, DeMeesterSR, OezcelikA, et al.The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg2011;253:271. CrossRef

326. MannerH, MayA, PechO, et al.Early Barrett's carcinoma with "low‐risk" submucosal invasion: long‐term results of endoscopic resection with a curative intent. Am J Gastroenterol2008;103:2589. CrossRef

327. BadreddineRJ, PrasadGA, LewisJT, et al.Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol2010;8:248. CrossRef

328. WaxmanI, RajuGS, CritchlowJ, et al.High‐frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high‐grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol2006;101:1773. CrossRef

329. LarghiA, LightdaleCJ, MemeoL, et al.EUS followed by EMR for staging of high‐grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc2005;62:16. CrossRef

330. SamplinerRE. Endoscopic ablative therapy for Barrett's esophagus. Gastrointest Endosc2004;59:66. CrossRef

331. BergmanJJ. Latest developments in the endoscopic management of gastroesophageal reflux disease and Barrett's esophagus: an overview of the year's literature. Endoscopy2006;8:122. CrossRef

332. LeggettCL, PrasadGA. High‐grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: the role of endoscopic eradication therapy. Curr Opin Gastroenterol2012;28:354. CrossRef

333. OverholtBF, LightdaleCJ, WangKK, et al.; International Photodynamic Group for High‐Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high‐grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc2005;62:488. CrossRef

334. OverholtBF, WangKK, BurdickJS, et al.; on behalf of the International Photodynamic Group for High‐Grade Dysplasia in Barrett's Esophagus. Five‐year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high‐grade dysplasia. Gastrointest Endosc2007;66:460. CrossRef

335. BergmanJJ. Radiofrequency energy ablation of Barrett's esophagus: the best is yet to come!Gastrointest Endosc2007;65:200. CrossRef

336. SpechlerSJ, SouzaRF. Stem cells in Barrett's esophagus: HALOs or horns?Gastrointest Endosc2008;68:41. CrossRef

337. FleischerDE, OverholtBF, SharmaVK, et al.Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5‐year follow‐up. Gastrointest Endosc2008;68:867. CrossRef

338. ShaheenNJ, SharmaP, OverholtBF, et al.Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med2009;360:2277. CrossRef

339. SoetiknoRM, GotodaT, NakanishiY, et al.Endoscopic mucosal resection. Gastrointest Endosc2003;57:567. CrossRef

340. PechO, MayA, GossnerL, et al.Management of pre‐malignant and malignant lesions by endoscopic resection. Best Pract Res Clin Gastroenterol2004;18:61. CrossRef

341. PetersFP, KaraMA, CurversWL, et al.Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol2007;19:311. CrossRef

342. TomizawaY, IyerPG, Wong Kee SongLM, et al.Safety of endoscopic mucosal resection for barrett's esophagus. Am J Gastroenterol2013;108:1440. CrossRef

343. PouwRE, SeewaldS, GondrieJJ, et al.Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut2010;59:1169. CrossRef

344. EllC, MayA, PechO, et al.Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc2007;65:3. CrossRef

345. PrasadGA, WangKK, ButtarNS, et al.Long‐term survival following endoscopic and surgical treatment of high‐grade dysplasia in Barrett's esophagus. Gastroenterology2007;132:1226. CrossRef

346. PechO, BehrensA, MayA, et al.Long‐term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high‐grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut2008;57:1200. CrossRef

347. FleischerDE, OdzeR, OverholtBF, et al.The case for endoscopic treatment of non‐dysplastic and low‐grade dysplastic Barrett's esophagus. Dig Dis Sci2010;55:1918. CrossRef

348. El‐SeragHB, GrahamDY. Routine polypectomy for colorectal polyps and ablation for Barrett's esophagus are intellectually the same. Gastroenterology2011;140:386. CrossRef

349. GrayNA, OdzeRD, SpechlerSJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol2011;106:1899. CrossRef

350. GuptaN, MathurSC, DumotJA, et al.Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett's esophagus?Gastrointest Endosc2012;75:11. CrossRef

351. BronnerMP, OverholtBF, TaylorSL, et al.; International Photodynamic Therapy Group for High‐Grade Dysplasia in Barrett's Esophagus. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high‐grade dysplasia. Gastroenterology2009;136:56. CrossRef

352. ZhouC, TsaiTH, LeeHC, et al.Characterization of buried glands pre‐ and post‐radiofrequency ablation using three‐dimensional optical coherence tomography. Gastrointest Endosc2012;76:32. CrossRef

353. AndersM, LucksY, El‐MasryMA, et al.Subsquamous extension of intestinal metaplasia is detected in 98% of cases of neoplastic barrett's esophagus. Clin Gastroenterol Hepatol2013;12:405. CrossRef

354. GondrieJJ, PouwRE, SondermeijerCM, et al.Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy2008;40:370. CrossRef

355. FleischerDE, OverholtBF, SharmaVK, et al.Endoscopic radiofrequency ablation for Barrett's esophagus: 5‐year outcomes from a prospective multicenter trial. Endoscopy2010;42:781. CrossRef

356. ShaheenNJ, OverholtBF, SamplinerRE, et al.Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology2011;141:460. CrossRef

357. VaccaroBJ, GonzalezS, PonerosJM, et al.Detection of intestinal metaplasia after successful eradication of Barrett's esophagus with radiofrequency ablation. Dig Dis Sci2011;56:1996. CrossRef

358. WilsonKT, FuS, RamanujamKS, et al.Increased expression of inducible nitric oxide synthase and cyclooxygenase‐2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res1998;58:2929.

359. ButtarNS, WangKK, LeontovichO, et al.Chemoprevention of esophageal adenocarcinoma by COX‐2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology2002;122:1101. CrossRef

360. LevineMS, ChuP, FurthEE, et al.Carcinoma of the esophagus and esophagogastric junction: sensitivity of radiographic diagnosis. AJR Am J Roentgenol1997;168:1423. CrossRef

361. EsfandyariT, PotterJW, VaeziMF. Dysphagia: a cost analysis of the diagnostic approach. Am J Gastroenterol2002;97:2733. CrossRef

362. DubeczA, GallI, SolymosiN, et al.Temporal trends in long‐term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol2012;7:443. CrossRef

363. RiceTW, RuschVW, IshwaranH, et al.Cancer of the esophagus and esophagogastric junction: data‐driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer2010;116:3763. CrossRef

364. NiemanDR, PetersJH. Treatment strategies for esophageal cancer. Gastroenterol Clin North Am2013;42:187. CrossRef

365. RiceTW, RuschVW, Apperson‐HansenC, et al.Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:1. CrossRef

366. EdgeSB, ByrdDR, ComptonCC, et al. (eds). AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2009.

367. SiewertJR, SteinHJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg1998;85:1457. CrossRef

368. EguchiT, NakanishiY, ShimodaT, et al.Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol2006;19:475. CrossRef

369. WallaceMB, NietertPJ, EarleC, et al.An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg2002;74:1026. CrossRef

370. FlamenP, LerutA, Van CutsemE, et al.Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202.

371. HeerenPA, JagerPL, BongaertsF, et al.Detection of distant metastases in esophageal cancer with (18)F‐FDG PET. J Nucl Med2004;45:980.

372. SmythEC, ShahMA. Role of (1)(8)F 2‐fluoro‐2‐deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol2011;17:5059. CrossRef

373. PuliSR, ReddyJB, BechtoldML, et al.Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta‐analysis and systematic review. World J Gastroenterol2008;14:1479. CrossRef

374. ThosaniN, SinghH, KapadiaA, et al.Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta‐analysis. Gastrointest Endosc2012;75:242. CrossRef

375. van VlietEP, Heijenbrok‐KalMH, HuninkMG, et al.Staging investigations for oesophageal cancer: a meta‐analysis. Br J Cancer2008;98:547. CrossRef

376. RiedelM, HauckRW, SteinHJ, et al.Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest1998;113:687. CrossRef

377. RiedelM, SteinHJ, MounyamL, et al.Extensive sampling improves preoperative bronchoscopic assessment of airway invasion by supracarinal esophageal cancer: a prospective study in 166 patients. Chest2001;119:1652. CrossRef

378. AjaniJA, BarthelJS, BentremDJ, et al.Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw2011;9:830.

379. van RossumPS, van HillegersbergR, LeverFM, et al.Imaging strategies in the management of oesophageal cancer: what's the role of MRI?Eur Radiol2013;23:1753. CrossRef

380. de GraafGW, AyantundeAA, ParsonsSL, et al.The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988. CrossRef

381. VeeramootooD, ShoreAC, WajedSA. Randomized controlled trial of laparoscopic gastric ischemic conditioning prior to minimally invasive esophagectomy, the LOGIC trial. Surg Endosc2012;26:1822. CrossRef

382. RiceTW, ZuccaroGJr, AdelsteinDJ, et al.Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg1998;65:787. CrossRef

383. MarietteC, SeitzJF, MaillardE, et al.; Federation Francaise de Cancerologie Digestive. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: 4005. http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4005.

384. PennathurA, ZhangJ, ChenH, et al.The "best operation" for esophageal cancer?Ann Thorac Surg2010;89:S2163. CrossRef

385. HulscherJB, van SandickJW, de BoerAG, et al.Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med2002;347:1662. CrossRef

386. WolffCS, CastilloSF, LarsonDR, et al.Ivor Lewis approach is superior to transhiatal approach in retrieval of lymph nodes at esophagectomy. Dis Esophagus2008;21:328. CrossRef

387. BirkmeyerJD, SiewersAE, FinlaysonEV, et al.Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:1128. CrossRef

388. MarkarSR, KarthikesalingamA, ThrumurthyS, et al.Volume‐outcome relationship in surgery for esophageal malignancy: systematic review and meta‐analysis 2000–2011. J Gastrointest Surg2012;16:1055. CrossRef

389. LuketichJD, Alvelo‐RiveraM, BuenaventuraPO, et al.Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg2003;238:486, discussion 494‐5.

390. LuketichJ, PennathurA, CatalanoPJ, et al.Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202). Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 4516. http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4516.

391. DonohoeCL, O′FarrellNJ, GrantT, et al.Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3‐point standard. Ann Surg2013;258:784. CrossRef

392. HerskovicA, MartzK, al‐SarrafM, et al.Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:1593. CrossRef

393. ShridharR, AlmhannaK, MeredithKL, et al.Radiation therapy and esophageal cancer. Cancer Control2013;20:97.

394. KleinbergL. Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. Semin Radiat Oncol2013;23:38. CrossRef

395. van HagenP, HulshofMC, van LanschotJJ, et al.Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:2074. CrossRef

396. CunninghamD, AllumWH, StenningSP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:11. CrossRef

397. CooperJS, GuoMD, HerskovicA, et al.Chemoradiotherapy of locally advanced esophageal cancer: long‐term follow‐up of a prospective randomized trial (RTOG 85‐01). Radiation Therapy Oncology Group. JAMA1999;281:1623. CrossRef

398. MinskyBD, PajakTF, GinsbergRJ, et al.INT 0123 (Radiation Therapy Oncology Group 94‐05) phase III trial of combined‐modality therapy for esophageal cancer: high‐dose versus standard‐dose radiation therapy. J Clin Oncol2002;20:1167. CrossRef

399. BedenneL, MichelP, BoucheO, et al.Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol2007;25:1160. CrossRef

400. StahlM, StuschkeM, LehmannN, et al.Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol2005;23:2310. CrossRef

401. ArnottSJ, DuncanW, GignouxM, et al.Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev2005;CD001799.

402. KelsenDP, GinsbergR, PajakTF, et al.Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:1979. CrossRef

403. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:1727. CrossRef

404. YchouM, BoigeV, PignonJP, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol2011;29:1715. CrossRef

405. MacdonaldJS, SmalleySR, BenedettiJ, et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725. CrossRef

406. LeeJ, Lim doH, KimS, et al.Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol2012;30:268. CrossRef

407. FuchsCS, TomasekJ, ChoJY, et al.REGARD: a phase III, randomized, double‐blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first‐line platinum‐ and/or fluoropyrimidine‐containing combination therapy. J Clin Oncol2012;30(Suppl 34; abstr LBA5). Available online at: http://meetinglibrary.asco.org/content/106221-133.

408. ArmaniosM, XuR, ForastiereAA, et al.Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro‐esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol2004;22:4495. CrossRef

409. StahlM, WalzMK, StuschkeM, et al.Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol2009;27:851. CrossRef

410. AjaniJA, XiaoL, RothJA, et al.A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol2013;24:2844. CrossRef

411. OttK, WeberWA, LordickF, et al.Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol2006;24:4692. CrossRef

412. LordickF, OttK, KrauseBJ, et al.PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol2007;8:797. CrossRef

413. WagnerAD, GrotheW, HaertingJ, et al.Chemotherapy in advanced gastric cancer: a systematic review and meta‐analysis based on aggregate data. J Clin Oncol2006;24:2903. CrossRef

414. Van CutsemE, MoiseyenkoVM, TjulandinS, et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first‐line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:4991. CrossRef

415. van MeertenE, EskensFA, van GamerenEC, et al.First‐line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer2007;96:1348.

416. BangYJ, Van CutsemE, FeyereislovaA, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376:687. CrossRef

417. WebbA, CunninghamD, ScarffeJH, et al.Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol1997;15:261. CrossRef

418. CunninghamD, StarlingN, RaoS, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:36. CrossRef

419. CrosbyT, HurtCN, FalkS, et al.Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol2013;14:627. CrossRef

420. LordickF, KangYK, ChungHC, et al.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncol2013;14:490. CrossRef

421. WaddellT, ChauI, CunninghamD, et al.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncol2013;14:481. CrossRef

422. OhtsuA, ShahMA, Van CutsemE, et al.Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. J Clin Oncol2011;29:3968. CrossRef

423. CatalanoV, GrazianoF, SantiniD, et al.Second‐line chemotherapy for patients with advanced gastric cancer: who may benefit?Br J Cancer2008;99:1402. CrossRef

424. FordH, MarshallA, WadsleyJ, et al.Cougar‐02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol2012;30(Suppl 34; abstr LBA4). Available online at: http://meetinglibrary.asco.org/content/105311-133.